Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  • Neurodegenerative Disorder
  • Huntington Disease (HD)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Recruiting

This study runs in
Cities
  • Christchurch
  • Ciudad Autonoma Buenos Aires
  • Edmonton
  • Englewood
  • Halifax
  • Iowa City
  • London
  • Parkville
  • Toronto
  • Ulm
  • Westmead
Trial Identifier:

NCT06667414 WE45491

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT06667414, WE45491 Trial Identifier
      Huntington Disease Condition
      Official Title

      Frequency of Selected Single Nucleotide Polymorphisms in Phase With the Mutant and Wild-Type HTT Alleles in Huntington Disease Gene Expansion Carriers

      Eligibility Criteria

      All Gender
      ≥25 Years & ≤ 60 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Have signed the Informed Consent Form (ICF)
      • Aged 25 to 60 years, inclusive, at the time of signing the ICF
      • Confirmation of Huntington Disease (HD) gene expansion mutation carrier status
      • Confirmation of Total Functional Capacity (TFC) ≥9 and Total Motor Score (TMS) >6 within 12 months prior to signing the ICF
      • Ability to tolerate blood draws
      Exclusion Criteria
      • None

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Huntington Disease (HD)

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now